Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00027274 · ClinicalTrials.gov registry record

Cancer in Inherited Bone Marrow Failure Syndromes

A clinical trial of Fanconi Anemia and Diamond-Blackfan Anemia, sponsored by National Cancer Institute (NCI).

Recruiting
Registry status
4,000
Enrollment target
2
Study locations

NCT00027274 is a study of Fanconi Anemia and Diamond-Blackfan Anemia that is actively recruiting participants, run by National Cancer Institute (NCI). The registered enrollment target is 4,000 participants, above the 70-participant average among 15 other Fanconi Anemia trials with a reported enrollment target (5614% higher). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00027274, a study of Fanconi Anemia and Diamond-Blackfan Anemia, is actively recruiting participants, sponsored by National Cancer Institute (NCI).

RECRUITING
Registry status
4,000 participants
Enrollment target
2
Study locations

Study Summary

Background: A prospective cohort of Inherited Bone Marrow Failure Syndrome (IBMFS) will provide new information regarding cancer rates and types in these disorders. Pathogenic variant(s) in IBMFS genes are relevant to carcinogenesis in sporadic cancers. Patients with IBMFS who develop cancer differ in their genetic and/or environmental features from patients with IBMFS who do not develop cancer. These cancer-prone families are well suited for cancer screening and prevention trials targeting those at increased genetic risk of cancer. Carriers of IBMFS pathogenic variant(s) are at increased risk of cancer. The prototype disorder is Fanconi's Anemia (FA); other IBMFS will also be studied. Objectives: To determine the types and incidence of specific cancers in patients with an IBMFS. To investigate the relevance of IBMFS pathogenic variant(s) in the carcinogenesis pathway of the sporadic counterparts of IBMFS-associated cancers. To identify risk factors for IBMFS-related cancers in addition to the primary germline pathogenic variant(s). To determine the risk of cancer in IBMFS carriers. Eligibility: North American families with a proband with an IBMFS. IBMFS suspected by phenotype, confirmed by pathogenic variant(s) in an IBMFS gene, or by clinical diagnostic test. Fanconi's anemia: birth defects, marrow failure, early onset malignancy; positive chromosome breakage result. Diamond-Blackfan anemia: pure red cell aplasia; elevated red cell adenosine deaminase. Dyskeratosis congenita: dysplastic nails, lacey pigmentation, leukoplakia; marrow failure. Shwachman-Diamond Syndrome: malabsorption; neutropenia. Amegakaryocytic thrombocytopenia: early onset thrombocytopenia. Thrombocytopenia absent radii: absent radii; early onset thrombocytopenia. Severe Congenital Neutropenia: neutropenia, pyogenic infections, bone marrow maturation arrest. Pearson's Syndrome: malabsorption, neutropenia, marrow failure, metabolic acidosis; ringed sideroblasts. Other bone

Study Locations (2)

Maryland

  • National Institutes of Health Clinical Center - Bethesda
  • National Cancer Institute - Shady Grove - Rockville

Trial Details

FieldValue
Enrollment Target 4,000 participants
Start Date 2001-11-28

Sponsor

National Cancer Institute (NCI)

3,257 total trials

What the Registry Record Tells You About NCT00027274

The ClinicalTrials.gov registry entry for NCT00027274 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 4,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 70-participant average among 15 other Fanconi Anemia trials with a reported enrollment target (5614% higher). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Fanconi Anemia appearing as the primary indexed condition, and to 0 interventions.

NCT00027274 reports 2 study locations spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT00027274 about?

NCT00027274 is a clinical study titled "Cancer in Inherited Bone Marrow Failure Syndromes". Background: A prospective cohort of Inherited Bone Marrow Failure Syndrome (IBMFS) will provide new information regarding cancer rates and types in these disorders. Pathogenic variant(s) in IBMFS genes are relevant to carcinogenesis in sporadic cancers. Patients with IBMFS who develop cancer diff...

What is the current status of trial NCT00027274?

This trial is currently recruiting. The enrollment target is 4,000 participants. The study started on 2001-11-28.

What conditions does trial NCT00027274 study?

This clinical trial studies the following conditions: Fanconi Anemia, Diamond-Blackfan Anemia, Dyskeratosis Congenita, Shwachman-Diamond Syndrome, Inherited Bone Marrow Failure Syndrome, Aplastic Anemia.

Who is sponsoring clinical trial NCT00027274?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00027274 being conducted?

This trial has 2 study locations across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Fanconi Anemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.